ReviewMetabolism: clinical and experimental2016
Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Review in Metabolism: clinical and experimental, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed.
- Weakly supervised deep learning distinguishes alcohol-associated from metabolic dysfunction-associated steatohepatitis on H&E whole-slide images.Journal of pathology informatics · 2026Article
- MELD and the Risk of Mortality Between Black and White Patients with Advanced Fibrosis.Digestive diseases and sciences · 2026Article
- Single-cell and spatial omics in liver identify cell-cell communication regulators in aging and insulin resistance.Metabolism: clinical and experimental · 2026Article
- Article
- Reliability Assessment of Metal Quantification in Formalin-fixed, Paraffin-embedded Human Liver Tissue for Studying Liver Diseases.Research square · 2026Article
- Evolving B-mode ultrasound-based techniques for assessing metabolic dysfunction-associated steatotic liver disease: Now and beyond.Liver research (Beijing, China) · 2026Review
- Protective Effects of Cashew Apple Bagasse and Its Hydroethanolic Extract Against Fatty Liver in Rats.Antioxidants (Basel, Switzerland) · 2026Article
- Targeting the Gut-Liver Mitochondria Axis in MASLD: Mechanisms and Therapeutic Perspectives.Current medical science · 2026Review
- Targeting lanosterol synthase alleviates MASLD by promoting fatty acid catabolism.Cellular and molecular life sciences : CMLS · 2026Article
- Restoring Mitochondrial Homeostasis: Therapeutic Strategies for Metabolic Dysfunction-Associated Fatty Liver Disease.International journal of molecular sciences · 2026Review
- Article
- Bridging the Gap Between Static Histology and Dynamic Organ-on-a-Chip Models.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Effects of Japan tallow on gut microbiota in type 2 diabetic mice.Nutrition & metabolism · 2026Article
- Affibody-based optical imaging probe for noninvasive detection of liver fibrosis.Theranostics · 2026Article
- Capsinoids treatment reduces steatosis with consequent attenuation in the progression of metabolic dysfunction-associated steatotic liver disease in obese rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- Terpenoid-enrichedExtracellular vesicles and circulating nucleic acids · 2026Article
- Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.Frontiers in immunology · 2026Review
- Development of automated machine learning models in predicting colorectal adenoma in metabolic-associated steatotic liver disease.Frontiers in medicine · 2026Article
- Article
- ACT001 alleviates MASLD through gut microbiota-bile acid-FXR axis in mice.Annals of medicine · 2025Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the liver injury most often associated with disorders of insulin resistance, including obesity, diabetes and the metabolic syndrome. The term encompasses several patterns of liver injury, including a relatively benign condition of steatosis without hepatocellular injury, nonalcoholic steatohepatitis (NASH), and a pattern of zone 1 steatosis, inflammation and fibrosis mainly observed in prepubertal children. Staging and grading systems have been developed to characterize the histological changes in NAFLD, mainly as a tool for clinical research. The histological features of NAFLD across these different manifestations and the scoring systems used to evaluate disease severity are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.